Market Access Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go... Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.
News Merck joins the Trump MFN gang with IVF deal Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.
News AstraZeneca joins Pfizer in MFN pricing deal with US AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.
News TrumpRx, BlinkRX, GoodRx – what's going on in DTC sales? Possible implications of TrumpRx, the federal direct-to-consumer sales channel, are starting to emerge ahead of its scheduled launch next year.
News Pharma tariffs yet to emerge as Trump seeks more deals Donald Trump looks set to delay the introduction of his tariffs on pharma imports in order to negotiate more deals with drugmakers on drug pricing.
News Trump, Pfizer announce MFN deal; Lilly, others to come At the White House today, President Trump and Pfizer CEO Albert Bourla announced the first of many deals to secure MFN drug prices for US consumers.
News Kyverna rises on stiff person syndrome data Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.